Can Fite Biopharma Financials - Benzinga

Can Fite Biopharma Ltd

CANFAMEX

Trade with Public

Trade with Public

$3.40

0.030.89%

At close: Aug 28, 5:00 PM EST

$3.40

N/A

After Hours: 6:45 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Compare Stock Report

Can Fite Biopharma Financials

Can Fite Biopharma (CANF) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday

U.S. stock futures slightly lower. UiPath joins S&P Midcap 400, Agios receives FDA approval, Can Fite Biopharma announces reverse split.

Avi Kapoor

Nasdaq Down 1%; Medtronic Earnings Top Views

Avi Kapoor

Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings

Avi Kapoor

PRO
Can-Fite BioPharma FY24 Net Loss $7.88M

Benzinga Newsdesk

PRO
Can-Fite BioPharma 1H EPS $(0.00), Same YoY; Revenue $316K Down From $392K YoY

Financial ResultsRevenues for the six months ended June 30, 2024 were $0.32 million compared to revenues of $0.39 million for the same period in 2023. Revenues for the six months ended June 30, 2024 and June 30, 2023

Benzinga Newsdesk

Can Fite Biofarma: Q4 Earnings Insights

Benzinga Insights